Revvity, Inc. has launched the IDS i20™, an innovative platform designed to automate chemiluminescence immunoassays (ChLIA). Developed by EUROIMMUN, this CE marked and FDA listed instrument enables laboratories to streamline specialty testing processes, improving efficiency and reducing manual workload.
Benefits for Lab Managers:
- Increased Throughput: Processes up to 140 tests per hour, enhancing laboratory productivity.
- Versatile Testing: Supports 20 analytes from six diagnostic specialties, allowing for test consolidation.
- Operational Efficiency: Continuous loading and integrated reagent cooling minimize downtime.
- User-Friendly Interface: Advanced software with intuitive design simplifies operation and training.
- Space-Saving Design: Compact footprint fits seamlessly into existing laboratory setups.
The IDS i20™ platform offers lab managers a reliable and efficient solution for automating specialty testing. Its high throughput and user-centric design contribute to improved laboratory workflows and resource optimization.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing."
